EUR/USD
1.16212
-0.084%
Gold
4060.43
-1.066%
Oil
61.426
0.179%
USD/JPY
153.106
0.185%
GBP/USD
1.33145
0.024%
GBP/JPY
203.858
0.210%
Real-time News
Toyota: The groups global sales in September increased by 2.8% year-on-year to 949,153 vehicles.Toyota: Domestic car production in Japan increased by 8.5% year-on-year to 301,626 units in September.According to RIA Novosti: Russian air defense forces shot down 193 Ukrainian drones last night.On October 27th, CLSA reported that with the increasing proportion of innovative drugs and accelerating earnings growth, it believes the current pullback represents a healthy consolidation, providing an attractive opportunity for next years deployment. CLSA believes that delays in the execution of CSPC Pharmaceutical Groups (01093.HK) business expansion have weakened investor confidence, creating a more attractive buying opportunity. Assuming business expansion resumes as expected, its price-to-earnings valuation remains very attractive. The bank also believes that several smaller business expansion deals are likely to be completed before the end of the year, with third-quarter results likely to be a near-term catalyst. The bank believes there is a high probability that large business expansion deals will achieve significant progress by next year. CLSA has a "High Conviction Outperform" rating on CSPC Pharmaceutical Group with a target price of HK$17.4. Regarding Sinopharm Group (01099.HK), the bank believes that improved accounts receivable days and the launch of the 15th Five-Year Plan will support the recovery of earnings momentum. The current share price offers an attractive dividend yield and a low price-to-earnings ratio, and with continued improvement in operational efficiency, the stock has significant upside potential. CLSA has an "Outperform" rating on Sinopharm Group with a target price of HK$24.5.Futures News, October 27th. Economies.com analysts latest view today: International spot gold prices have fallen in recent intraday trading, under pressure from continued movement below the 50-day exponential moving average (EMA50), reducing the likelihood of a near-term rebound. This trend reinforces the dominance of the bearish correction trend, limiting attempts by international spot gold to resume its upward trajectory. Meanwhile, the relative strength index (RSI) formed a death cross after breaking out of its previously oversold condition, exacerbating downward pressure on prices and paving the way for further declines in subsequent trading.
